Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses treating patients with non-small cell lung cancer (NSCLC) who do not have an actionable oncogenic driver.
Updates on Recent Advances and Treatments for Hematologic Malignancies
March 22nd 2023In an interview with Targeted Oncology, Guenther Koehne, MD, PhD, provided an overview of The Summit of Americas on Immunotherapies for Hematologic Malignancies and some of the recent and exciting advances being seen in the hematology space.
Read More
Patritumab Deruxtecan Elicits Clinical Activity in Some Patients With Lung and Breast Cancer
March 20th 2023Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.
Read More
Coformulation of Pembrolizumab/Vibostolimab Fails to Show PFS Benefit in NSCLC
March 20th 2023The phase 3 KeyVibe-002 trial of pembrolizumab and vibostolimab did not meet its primary end point of progression-free survival and was numerically less effective than docetaxel in patients with non–small cell lung cancer
Read More
AI Continues to Push the Field of Radiation Oncology Forward
March 19th 2023In an interview with Targeted Oncology, Matthew Manning, MD, FASTRO, discussed the many radiation oncology tasks that have been improved with AI and its prospective utility in cancer diagnosis and treatment decisions.
Read More
2 Clarke Drive
Cranbury, NJ 08512